Novo Nordisk Annual Report 2021
Financial statements of the parent company
Equity statement
DKK million
Balance at the beginning of the year
Appropriated from net profit
Appropriated from net profit to net revaluation reserve
Exchange rate adjustments of investments in subsidiaries
Effect of cash flow hedges transferred to the income statement
Fair value adjustments of cash flow hedges for the year
Development costs
Other adjustments
Transactions with owners:
Total dividend for the year
Interim dividends paid during the year
Dividends paid for prior year
Reduction of the B share capital
Purchase of treasury shares
Share-based payments (note 3)
Tax related to restricted stock units
Balance at the end of the year
Proposed appropriation of net profit:
Interim dividend for the year
Final dividend for the year
Appropriated to net revaluation reserve
Transferred to retained earnings
Distribution of net profit
Reserve for cash
Net
flow hedges and
Develop-
Share revaluation
exchange rate
ment costs
Retained
capital
reserve
adjustments
reserve
earnings
2021
2020
470
9,749
1,617
959
50,241
63,036
57,432
(8)
6,312
1,614
10
(3,227)
Novo Nordisk Annual Report 2021 99
Please refer to note 4.2 in the consolidated financial statements for details
on the average number of shares, treasury shares and total number of A
and B shares in Novo Nordisk A/S.
Development in share capital
17,500
17,500
24,995
DKK million
A share
capital
B share
Total
share
capital
capital
6,312
(3,902)
Beginning of 2017
107
403
510
1,624
(1,689)
Cancelled in 2017
(10)
500
Cancelled in 2018
(3,227)
1,940
(10)
490
Cancelled in 2019
(10)
480
Cancelled in 2020
(10)
470
259
(259)
Cancelled in 2021
(8)
462
1,904
1,904
(179)
Share capital at the end of the year
107
355
462
23,711
23,711
21,066
(8,021)
(8,021)
(7,570)
(13,496) (13,496)
(12,551)
8
(19,447)
(19,447)
(16,855)
383
383
327
190
190
22
462
17,675
(1,600)
1,218
52,714
70,469
63,036
8,021
7,570
15,690
13,496
6,312
(3,902)
17,500
24,995
47,523
42,159View entire presentation